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192Asthmaandchronic obstructivepulmonary disease (COPD)arechronic inflammatory
diseases of theairway, although thedrivers and site of the inflammationdiffer between
diseases. Asthmatics with a neutrophilic airway inflammation are associated with a
poor response to corticosteroids, whereas asthmatics with eosinophilic inflammation
respond better to corticosteroids. Biologicals targeting the Th2-eosinophil nexus
such as anti–interleukin (IL)-4, anti–IL-5, and anti–IL-13 are ineffective in asthma as a
whole but are more effective if patients are selected using cellular (eg, eosinophils)
ormolecular (eg, periostin) biomarkers. This highlights the key roleof individual inflam-
matory mediators in driving the inflammatory response and for accurate disease
phenotyping to allow greater understanding of disease and development of
patient-oriented antiasthma therapies. In contrast to asthmatic patients, corticoste-
roids are relatively ineffective inCOPDpatients. Despite stratificationofCOPDpatients,
the results of targeted therapyhaveproveddisappointingwith the exception of recent
studies using CXC chemokine receptor (CXCR)2 antagonists. Currently, several other
novel mediator-targeted drugs are undergoing clinical trials. As with asthma specif-
ically targeted treatmentsmaybeofmost benefit in specificCOPDpatient endotypes.
The use of novel inflammatory mediator-targeted therapeutic agents in selected pa-
tients with asthma or COPD and the detection of markers of responsiveness or nonres-
ponsiveness will allow a link between clinical phenotypes and pathophysiological
mechanisms tobedelineated reaching thegoal of endotypingpatients. (Translational
Research 2016;167:192–203)Abbreviations: AHR ¼ airway hyperresponsiveness; ACQ ¼ Asthma Control Questionnaire;
ACOS ¼ asthma-COPD overlap syndrome; BAL ¼ bronchoalveolar lavage; CLCA1 ¼ chloride
channel regulator 1; COPD ¼ chronic obstructive lung disease; CS ¼ corticosteroids; CXCR ¼
CXCchemokine receptor; EGF¼ epidermal growth factor; EGFR¼ epidermal growth factor re-
ceptor; FKBP51 ¼ FK506-binding protein 51; FP ¼ fluticasone propionate; FEV1 ¼ Forced expira-
tory volume in 1 second; FeNO¼ fraction of exhaled nitric oxide; GR¼ glucocorticoid receptor;
GM-CSF ¼ Granulocyte-macrophage colony-stimulating factor; HDACs ¼ histone deacety-
lases; HNE¼ Human neutrophil elastase; IgE¼ Immunoglobulin E; ICS¼ inhaled corticosteroids;
LABAs ¼ Long-acting beta-adrenoceptor agonists; mRNA ¼ messenger RNA; MAbs ¼ mono-
clonal antibodies; PDE ¼ phosphodiesterase; PI3K ¼ phosphoinositide-3-kinase; RT-qPCR ¼
Real time quantative polymerase chain reaction; SAL ¼ salmeterol; SERPINB2 ¼ serpin pepti-
dase inhibitor; clade B ¼member 2; sIL-4R ¼ soluble IL-4 receptor; GOLD ¼ The Global Initiative
forChronicObstructive LungDisease; TSLP¼ Thymic stromal lymphopoietin; TORCH¼ Towards a
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Asthma and chronic obstructive pulmonary disease
(COPD) affect more than 500 million people worldwide
representing the 2 most common chronic inflammatory
diseases of the lower airways.1,2 This review
summarizes some of the recent evidence indicating
how the use of therapeutics targeting specific
inflammatory mediators has indicated their role in
disease pathophysiology and also highlighted the
importance of subphenotyping these diseases to
optimize the response to these targeted drugs.
The current consensus definition of asthma is ‘‘an
(sic) heterogeneous disease, usually characterized by
chronic airway inflammation. It is defined by the history
of respiratory symptoms such as wheeze, shortness of
breath, chest tightness and cough that vary over time
and in intensity, together with variable airflow obstruc-
tion.’’1 Patients with asthma have variable airflow
obstruction and airway hyper-responsiveness (AHR).3
Asthma affects 10%–12% of the adult population in
Europe and most high (V20.65 billion) annual costs of
asthma in Europe are because of patients with severe
disease who do not respond well to conventional
anti-inflammatory corticosteroids that is the mainstay
treatment of mild-moderate asthma.4
The analysis of airway biopsies after bronchoscopy
and the introduction of induced sputum analysis allowed
the inflammatory nature of the asthmatic airways to be
confirmed.5-7 These analyses revealed the presence of
eosinophils and Th2 cytokines particularly interleukin
(IL)-2 and IL-4,8 which emphasized the Th2-driven na-
ture of asthmatic inflammation. As a result asthma was,
for a long time, considered as a single Th2-driven eosin-
ophilic disease whose diagnosis is based on the patient
presenting with an intermittent wheeze, dyspnea, and
cough. However, it was clear that the presentation and
natural history of the disease differ between patients;
some asthmatics undergo clinical remission during
adolescence, some patients have more severe disease,
some asthmatics are nonallergic or atopic, whereas others
have exercise-induced asthma.9,10
Later studies showed that although eosinophils were
present in many asthmatic biopsies, some subjects,
particularly those with more severe disease, also
demonstrated increased levels of neutrophils.11 Simi-
larly, Gibson et al have shown different types of sputum
cellular composition in asthma with some subjects hav-
ing predominant eosinophilia, others more neutrophilic
or with a mixed cell composition, and another group
with paucicellular sputum.12,13 This has led to the idea
of asthma being a complex disease or even a group of
‘‘diseases’’ caused by different pathophysiological
mechanisms.9,10The Global Initiative for Chronic Obstructive Lung
Disease guidelines define COPD as ‘‘a common pre-
ventable and treatable disease, characterized by persis-
tent airflow limitation that is usually progressive and
associated with an enhanced chronic inflammatory
response in the airways and the lung to noxious particles
or gases. Exacerbations and comorbidities contribute to
the overall severity in individual patients.’’14 COPD is
expected to rise from the 4th to the 3rd leading cause
of morbidity and mortality worldwide within the next
5 years.14 According to the World Health Organization,
approximately 3 million people in the world die as a
consequence of COPD every year.15 The estimated
annual costs of COPD are $24 billion and 70% are
related to exacerbations requiring hospitalization.2 In
developed countries, the leading risk factor for COPD
is cigarette smoking with smokers constituting more
than 90% of COPD patients.14 In less-well developed
countries, biomass fuel used in cooking and other envi-
ronmental pollutants are major factors.16,17
The pathologic features of COPD are lung paren-
chymal destruction (pulmonary emphysema), inflam-
mation of the small (peripheral) airways (respiratory
bronchiolitis), and inflammation of the central air-
ways. Inflammation occurs within all these compart-
ments (central and peripheral airways and lung
parenchyma).18 The major sites of airflow obstruction
are the small airways and lung parenchyma in
COPD.19,20
CORTICOSTEROID RESPONSIVENESS IN ASTHMA
Asthma was implicated as a chronic inflammatory dis-
ease, and this was confirmed when the potent
anti-inflammatory prednisolone was shown to be of
benefit in patients with asthma. Some of the original
studies with oral prednisolone highlighted that blood
levels of eosinophils were not altered in patients who
were more refractory to treatment. This provided early ev-
idence for the concept of relatively corticosteroid-resistant
asthma.21 However, the introduction of inhaled corticoste-
roids (ICSs) resulted in such a dramatic improvement in
the asthma symptoms of most asthmatics22,23 that these
earlier studies indicating that only 40% of asthmatics
responded well, at least in terms of an improvement in
forced expiratory volume in 1 second (FEV1), was
ignored. In common with most chronic inflammatory
diseases, corticosteroids are able to attenuate all
measures of inflammation in asthmatic airways leading
to a reversal in the decline in FEV1 associated with the
disease and a reduction in AHR back to normal levels.
However, ICSs do not cure asthmatics as many of the
symptoms of asthma and the inflammation return on
their discontinuation.24,25
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oral corticosteroids, termed severe asthmatics, often have
more frequent exacerbations requiring hospitalization
and depression associated with the chronic nature of the
disease,which is not controlled by conventional therapy.9
There is an urgent need for new effective anti-
inflammatory drugs that could treat or even ultimately
cure these patients as they will have a profound effect
on an individual patient’s welfare and also on the huge
associated societal costs.24 Relative corticosteroid insen-
sitivity is seen in a subset of patients across all chronic
inflammatory diseases with a commensurate increase in
healthcare and societal costs.26
Asthma is now recognized as a syndrome with many
potential phenotypes and endotypes and understanding
these is essential in determining the most effective ther-
apeutic regimen suitable for each patient.10 Several
large consortia in Europe and the USA, as well as indi-
vidual research centers, have been instrumental in
defining subgroups of asthma and severe asthma based
on clinical features.10,27,28 For example, 5 clusters of
asthma were identified by SARP29 and 4 clusters from
Leicester.30 In both studies, severe asthmatics were
distributed among several clusters. The therapeutic
efficacy of some drugs was enhanced by taking cytopa-
thologic and histopathologic inflammatory characteris-
tics and or genomic signatures into account. For
instance, neutrophilic airway inflammation was associ-
ated with poor corticosteroid responses31 and cortico-
steroid treatment guided by eosinophilic inflammation
led to better disease outcome than standard clinical
management.32,33 Interestingly, patient selection
guided by sputum eosinophils also appears to be a
better predictor of a patient’s responses to anti–IL-5
antibody treatment.34-36INHIBITING INFLAMMATORY MEDIATORS IN ASTHMA
More than 100 mediators have now been implicated
in asthmatic inflammation, including multiple cyto-
kines, chemokines, and growth factors.24 Blocking a
single mediator is therefore unlikely to be very effective
in this complex disease, and mediator antagonists have
so far not proved to be very effective compared with
drugs that have a broad spectrum of anti-inflammatory
effects, such as corticosteroids. However, blocking
Th2 cytokines such as IL-4, IL-5, and IL-13 despite
not been completely explored has shown some prom-
ising results in selected patients with asthma.IL-5-TARGETED THERAPY IN ASTHMA
The Th2 cell cytokine, IL-5, plays an important role
in eosinophil maturation, differentiation, recruitment,
and survival. IL-5 knockout mice appeared to confirma role in asthma models in which eosinophilia and
AHR are markedly suppressed. The humanized anti–
IL-5 monoclonal antibodies (MAbs), mepolizumab
(formerly termed SCH55700) and reslizumab (formerly
Res-5-0010), have been developed for clinical use.37
Another fully humanized MAb benralizumab (previ-
ously named MEDI-563) instead targets eosinophils
by binding IL-5 receptor a (IL-5Ra) inhibiting IL-5
binding and inducing eosinophil apoptosis through
antibody-dependent cell-mediated cytotoxicity.38
It has been demonstrated in earlier studies that using
mepolizumab in mild-moderate asthmatics was very
effective at reducing sputum and blood eosinophils
but had no effect on clinical signs and symptoms sug-
gesting that the concept of asthma as a Th2-driven
eosinophilic disease was incorrect.39 Subsequent
studies showed that the same dose of mepolizumab
only partially reduced eosinophil numbers within bron-
chial biopsies of asthmatics, which may have accounted
for the persistence of symptoms.40 However, this
approach was unable to distinguish potential responders
from nonresponders.
On the basis of earlier work showing a cluster of
patients with severe asthma had inappropriate levels of
sputum eosinophils, Haldar et al examined whether
reducing eosinophilia in these patients would have any
effect on the clinical features of asthma particularly
exacerbations.41 Sixty-one subjects who had refractory
eosinophilic asthma and a history of recurrent severe
exacerbations received intravenous infusions of 750 mg
mepolizumab monthly for 1 year in a randomized,
double-blind, placebo-controlled, parallel-group study
(Current Controlled Trials number, ISRCTN75169762.).
Mepolizumab significantly lowered eosinophil counts in
the blood (P, 0.001) and sputum (P5 0.002), and this
was associated with a reduction in exacerbations (2.0 vs
3.4 mean exacerbations per subject) compared with pla-
cebo. There were no significant differences between the
groups with respect to symptoms, FEV1 after bronchodi-
lator use, or AHR.41
An unblinded follow-up analysis of 56 of the original
61 subjects for 12 months indicated that withdrawal of
mepolizumab resulted in an increase in blood and
sputum eosinophils that preceded the rise in exacerba-
tions. Twelve months after stopping mepolizumab,
exacerbation frequency was similar in the placebo and
mepolizumab groups. Not unexpectedly, no effects on
FEV1 or fraction of exhaled nitric oxide were seen after
cessation of mepolizumab therapy. This supports the
concept that these events are related and have patho-
physiological importance.42
These results were replicated in a follow-up multi-
center, double-blind, placebo-controlled study
(ClinicalTrials.gov number, NCT01000506) in 621
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study. There was a 52% reduction in clinically signifi-
cant exacerbations with 75 mg mepolizumab, and blood
eosinophils appeared to be the best predictor of
response.35
Furthermore, similar results were observed whether
mepolizumab was delivered intravenously (75 mg) or
subcutaneously (100 mg) for 32 weeks with a 47% and
53% reduction in exacerbations, respectively. This study
(ClinicalTrials.gov number, NCT01691521) also re-
ported an increase inFEV1 in all patients receivingmepo-
lizumab of approximately 100 mL and a resultant
improvement in asthma quality of life and asthma control
questionnaire scores.36 One hundred milligrams of me-
polizumab given subcutaneously had a significant
glucocorticoid-sparing effect, reduced exacerbations,
and improved control of asthma symptoms in patients
requiring daily oral glucocorticoid therapy to maintain
asthma control (ClinicalTrials.gov number, NCT0169
1508).43
These latter 2 important new studies suggest that the
regular monthly treatment with subcutaneous injections
of mepolizumab reduce exacerbation rates by 50% in
asthmatic patients with persistent peripheral blood
eosinophilia and persistent symptoms despite
high-dose ICS and additional controller therapy, and
frequent exacerbations. Mepolizumab is also able to
reduce oral steroid requirement by 50% in similar
asthmatic patients who additionally required oral pred-
nisone to control their asthma.36,43,44
Two other anti–IL-5RMAbs, benralizumab and resli-
zumab, had effects similar to mepolizumab with respect
to decreasing rates in asthmatic patients with poorly
controlled disease and high levels of blood and/or
sputum eosinophils despite high doses of ICS therapy.
The anti–IL-5Ra MAb benralizumab delivered either
intravenously or subcutaneously reduced eosinophil
counts in airway mucosa and submucosa, sputum,
bone marrow, and peripheral blood.38 In a large
controlled clinical trial, benralizumab only reduced
exacerbation rates compared with placebo (57% vs
43%) in the subgroup of patients with persistent asthma
and high baseline blood eosinophils.45 There are
currently many ongoing controlled clinical trials inves-
tigating the efficacy and safety of the addition of
benralizumab to the standard of care in the treatment
of adult asthmatic patients with different levels of
asthma severity (NCT02075255, NCT02322775,
NCT01928771, and NCT02258542).
Reslizumab reduces sputum eosinophils in patients
with eosinophilic asthma that is poorly controlled with
high-dose ICSs compared with placebo.46 In 2 studies,
patients whose asthma was inadequately controlled by
medium-to-high doses of ICS-based therapy and whohad blood eosinophils .400 cells/mL and one or more
exacerbations in the previous year, intravenous reslizu-
mab had a significant reduction in the frequency of
asthma exacerbations compared with those receiving
placebo.47IL-13-TARGETED THERAPY IN ASTHMA
As part of the Th2 hypothesis of asthma, IL-13 has
been shown to play a critical role in various aspects of
airway inflammation and epithelial remodeling
including goblet cell metaplasia and epithelial-
mesenchymal signaling. This leads to increased subepi-
thelial fibrosis or airway smooth muscle hyperplasia.48
Blocking IL-13, but not IL-4, in animal models of
asthma prevents the development of AHR after allergen,
despite a strong eosinophilic response. In addition,
soluble IL-13Ra2 is effective in blocking the actions
of IL-13, including immunoglobulin E (IgE) produc-
tion, pulmonary eosinophilia, and AHR in animal
models of asthma.37
Airway epithelial cells are a major target for cortico-
steroids and their effectiveness in asthma may relate to
their ability to modulate the production of inflammatory
mediators from these cells, which have downstream
effects on other inflammatory cells. In an attempt to
address this issue, Woodruff et al collected epithelial
cells obtained by bronchial brushings from asthmatic
subjects undergoing a randomized controlled trial of
ICSs and from healthy subjects.49
Transcriptomic analysis of these cells identified 2
distinct groups termed Th2-high and Th2-low based
on the differential expression of IL-13–inducible genes
(periostin, chloride channel regulator 1, and serpin
peptidase inhibitor, clade B, member 2)—a Th2-high
signature. Corticosteroid treatment downregulated the
expression of these 3 genes and markedly upregulated
the expression of FK506-binding protein 51. High basal
expression of this Th2-high signature was associated
with a good clinical response to corticosteroids,
whereas high FK506-binding protein 51 expression
was linked to a poor clinical response. These results
were confirmed in primary epithelial cell cultures.
Overall, the Th2-high group was associated with
sputum eosinophilia and AHR and consistent with the
predictive value of sputum eosinophilia, the Th2-high
phenotype responded clinically to corticosteroids (CS)
resulting in reduced expression of these Th2 bio-
markers.49,50
Measurement of the Th2 signature in bronchial
epithelium depends on invasive airway sampling
and hence noninvasive biomarkers of this phenotype
are desirable. Sputum is a more accessible compart-
ment to determine airway Th2-high vs Th2-low
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tion (RT-qPCR) analysis of sputum cell pellets
from 37 asthmatic patients and 15 healthy control
subjects demonstrated that the gene expression levels
of chloride channel regulator 1 and periostin, but not
serpin peptidase inhibitor, clade B, member 2, were
significantly higher than normal in sputum cells
from asthmatic subjects.51 However, the composite
expression of IL-4, IL-5, and IL-13 messenger
RNA was able to demonstrate Th2-high status in
these patients. These were characterized by more se-
vere measures of asthma and increased blood and
sputum eosinophilia. This Th2-gene mean value
was stable at the upper and lower limits but at inter-
mediate levels raising issues about the utility of this
signal for these patients.51 The Th2-high signature is
a variable being correlated with local allergic signals
and eosinophilia52 and has also been linked to
markers of airway remodeling.50
A comparison of IgE levels, blood eosinophil
numbers, fraction of exhaled nitric oxide levels,
and serum periostin levels in 59 patients with
severe asthma indicated that serum periostin level
was the single best predictor of airway eosinophilia
(P 5 0.007).53 It made sense, therefore, to use perios-
tin levels as a biomarker for anti–IL-13 therapy partic-
ularly because some patients with uncontrolled asthma
continue to have increased levels of IL-13 in the
sputum, despite the use of systemic corticosteroids
and ICSs.54
Lebrikizumab, anMAb to IL-13, improved lung func-
tion in a randomized, double-blind, placebo-controlled
study of 219 adults who had asthma that was inade-
quately controlled despite inhaled glucocorticoid ther-
apy (ClinicalTrials.gov number, NCT00930163).55
Overall, the patients on lebrikizumab had a 5.5% in-
crease in FEV1 than those in the placebo group. When
patients were divided according to high or low serum
periostin levels, those with high periostin had greater
improvement in lung function with lebrikizumab
(8.2%) than those with low periostin levels (1.6%). Pa-
tient selection, however, is the key to success with these
drugs because lebrikizumab failed to increase FEV1 in
212 adult asthmatics not receiving ICSs irrespective of
periostin levels.56
Similarly, subcutaneous tralokinumab (formerly
CAT-354), an IL-13–neutralizing IgG4 MAb, improves
lung function but not global asthma control scores in
adults with moderate-to-severe uncontrolled asthma
despite controller therapies.57 There is an ongoing large
controlled clinical trial investigating the efficacy of tra-
lokinumab in adults and adolescents with oral
corticosteroid-dependent asthma (https://clinicaltrials.
gov/ct2/show/NCT02281357).IL-4-PATHWAY-TARGETED THERAPY IN PERSISTENT
ASTHMA
IL-4 analogs that act as antagonists have been devel-
oped, which fail to induce signal transduction and block
IL-4 effects in vitro. These IL-4 antagonists prevent the
development of asthma in vivo in animal models.37
However, the development of pascolizumab (SB
240683), a humanized anti–IL-4 antibody,58 and a
blocking variant of human IL-4 (BAY36-1677) has
apparently been discontinued.37
A soluble IL-4 receptor (sIL-4R) that acts as an IL-4R
antagonist and for this reason is a dual IL-4/IL-13
pathway antagonist, termed pitrakinra, has also been
developed. A single nebulized dose of sIL-4R prevents
the fall in lung function induced by glucocorticoid with-
drawal in moderate to severe asthmatics59 and allergen-
induced FEV1 decrease in atopic asthmatics.
60 Weekly
nebulization of sIL-4R for more than 3 months im-
proves asthma control.59 Interestingly amino acid
changes in the 30-end of the IL-4Ra gene or closely
proximal variants predict pitrakinra efficacy.61 Howev-
er, further studies in patients with milder asthma proved
disappointing and the clinical development of this com-
pound has now been discontinued.37
Dupilumab (SAR231893/REGN668) is a fully hu-
manized anti–IL-4Ra MAb, which reduced asthma ex-
acerbations when long-acting beta-adrenoceptor
agonists (LABAs) and ICSs were withdrawn from pa-
tients with persistent asthma, moderate-to-severe
asthma, and who had a blood eosinophil count
.300 cells/mL or a sputum eosinophil level .3%. This
was associated with improved lung function and reduced
levels of Th2-associated inflammatory markers.62 In
contrast, AMG 317, another fully humanized anti–IL-
4Ra MAb, did not demonstrate any clinical efficacy in
patients with moderate-to-severe asthma.63OTHER ANTI-INFLAMMATORY PATHWAYS UNDER
CLINICAL INVESTIGATION IN PERSISTENT ASTHMA
In a short 4-week double-blind randomized study,
MK-7123/SCH527123, a CXC chemokine receptor
(CXCR)2 antagonist, reduced sputum neutrophilia by
36% in patients with severe asthma, although it had
no effect on lung function or on an asthma quality of
life questionnaire.64 Longer studies are warranted in
these patients.
Despite good results in preclinical studies, brodalu-
mab, an anti–IL-17Ra MAb, had no effect on asthma
control questionnaire score, FEV1, symptom scores, or
number of symptom-free days in 302 subjects with inad-
equately controlled moderate-severe asthma taking
regular ICSs. Subgroup analysis of the high-
reversibility group was of uncertain significance and
Fig 1. Asthma occurs in the airway because of the combined responses of structural cells such as epithelial cells
and immune cells, macrophages and dendritic cells in response to aero allergens, viruses, or other environmental
challenges. This results in the production of a host of inflammatory mediators that drive the disease process. There
are at least 2 major types of asthma—Th2-high and Th2-low—dependent on the presence of selected Th2 molec-
ular signatures including periostin and high levels of sputum and blood eosinophils in response to Th2 cytokines
such as IL-4, IL-5, and IL-13. Asthmatic patients with uncontrolled severe disease despite high doses of ICSs and
having high eosinophils and blood periostin respond to anti–IL-5 and anti–IL-13 therapy. There is a negligible
clinical response to anti–IL-1, anti–IL-4, anti–IL-17, or TNF-a treatment. Non-Th2 patients are believed to
have a more mixed lymphocyte profile involving Th1 and Th2 cells. They respond to anti-CXCR2 antagonists
but not to anti–IL-1, anti–IL-8, or TNF-a treatment. Studies using anti–IL-17 or other antineutrophil approaches
are yet to be completed. ICS, inhaled corticosteroid; IFN, interferon; IgE, immunoglobulin E; IL, interleukin;
TNF, tumor necrosis factor.
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gov, NCT01199289).65 Secukinumab (AIN457), an
anti–IL-17 MAb that selectively neutralizes IL-17A, is
starting phase II trials in asthmatic subjects who are
not adequately controlled with ICSs and long-acting
b2-agonists (NCT01478360).
Thymic stromal lymphopoietin (TSLP) is a bronchial
epithelial cell–derived cytokine that may be important
in initiating allergic inflammation. MEDI9929
(formerly AMG 157) is a human anti-TSLP MAb that
binds human TSLP and prevents receptor interaction.66
Treatment with AMG 157 reduced allergen-induced
bronchoconstriction and blood and sputum before and
after allergen challenge.66 There is an ongoing clinicaltrial investigating the efficacy of MEDI9929 in not
well-controlled severe persistent asthma (https://www.
clinicaltrials.gov/ct2/show/NCT02054130).
SUMMARY ON THE CURRENT APPROACH OF
TARGETINGNOVEL ANTI-INFLAMMATORY PATHWAYS
IN ASTHMA
These classifications and biomarkers are useful as a
start (Fig 1) but are not optimal and do not provide
detailed information regarding biomarkers or pathways
involved in corticosteroid insensitivity or in Th2-low
asthma. In addition, there are still many unresolved is-
sues on the inclusion criteria of the asthmatic patients
in these trials. For example, considering the very low
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inhaled and oral routes), even in patients with severe
persistent asthma.67 We eagerly need objective mea-
sures of this compliance to avoid to erroneously attri-
bute difficult-to-control asthma to a reduced
responsiveness to corticosteroids.68 Another key issue
is represented by accurate differential diagnosis of
patients with severe persistent asthma to avoid the erro-
neous inclusion in these clinical trials of patients with
other diseases such as the Churg-Strauss syndrome,
chronic eosinophilic leukemia, lymphocyte-variant hy-
pereosinophilia, and idiopathic hypereosinophilic
syndrome that may mimick the clinical features of
asthma and are usually associated with minimal
response to ICSs but may respond to anti-Th2 cytokine
treatment.69 Furthermore, the Th2 signatures investi-
gated so far are not very specific and more selective
Th2 biomarkers such as the Th2 transcription factor
GATA-3 may be more rewarding70 and compounds tar-
geting this pathway are under clinical development.71
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
The progressive chronic airflow limitation in COPD
results from 2 major pathologic processes: remodeling
and narrowing of small airways and destruction of the
lung parenchyma (pulmonary emphysema) with conse-
quent loss of the alveolar attachments of these airways.
This results in diminished lung recoil, higher resistance
to flow, and closure of small airways at higher lung vol-
umes during expiration, with consequent air trapping in
the lung. This leads to the characteristic lung hyperinfla-
tion, which gives rise to the sensation of dyspnea and
decreased exercise tolerance. Both small-airway remod-
eling and narrowing and pulmonary emphysema result
from chronic peripheral lung inflammation.72
There are increased number of macrophages, neutro-
phils, T lymphocytes, dendritic cells, and B lympho-
cytes in the lower airways of patients with stable
COPD.19 However, the predominant inflammatory cell
type varies with disease severity, with an increased
number of neutrophils and B lymphocytes in the most
severe (III and IV) grades.19,20 Eosinophils are more
pronounced during viral-induced severe COPD exacer-
bations.73 In contrast to asthma, there is a preferential
increase in CD81 and CD41 cells associated with
the production of interferon gamma,74 although Th2
cytokines such as IL-4 are also increased in COPD pa-
tients.75 Th17 cell numbers are also increased in bron-
chial biopsies of COPD patients.76 The role of the
increased number of B lymphocytes in severe and
very severe COPD is unknown, but they may be associ-
ated with the increased presence of autoantibodies
directed against oxidized proteins.77INHIBITING INFLAMMATORY MEDIATORS IN COPD
Reduced response to the anti-inflammatory action of
corticosteroids in stable COPD. In contrast to asthma,
glucocorticoid treatment of stable COPD is rather inef-
fective in reducing airway inflammation and the decline
of lung function.78 A Cochrane review of the role of
regular long-term treatment with ICSs alone vs placebo
in patients with stable COPD has concluded that it
reduces significantly the mean rate of exacerbations and
the rate of decline of quality of life but not the decline
in FEV1 or mortality rates.
79 Current national and
international guidelines for the management of stable
COPD patients recommend the use of inhaled long-
acting bronchodilators, ICSs, and their combination for
maintenance treatment of moderate-to-severe stable
COPD.2 ICS treatment is also associated with adverse
effects such as increased risk of oropharyngeal
candidiasis, hoarseness, and pneumonia.79
Several large controlled clinical trials of inhaled com-
bination therapy with ICSs and LABAs in a single
device in stable COPD have shown that this combina-
tion therapy is well tolerated and produces a modest
but statistically significant reduction in the number of
severe exacerbations and improvement in FEV1, quality
of life, and respiratory symptoms in stable COPD
patients, with no greater risk of adverse effects than
that with use of either component alone. Increased
risk of pneumonia is a concern; however, this did not
translate into increased exacerbations, hospitalizations,
or deaths.80 In addition, the Towards a Revolution in
COPD Health study showed a 17% relative reduction
in mortality for more than 3 years for patients receiving
combined salmeterol and fluticasone propionate,
although this just failed to reach significance.81 Blood
eosinophil count is a promising biomarker of the
response to ICSs in COPD and could potentially be
used to stratify patients for different exacerbation rate
reduction strategies.82
Corticosteroid suppression of many inflammatory
genes requires recruitment of histone deacetylases
(HDACs) to the gene activation complex by the acti-
vated glucocorticoid receptor. Oxidative stress reduces
HDAC2 expression and activity, thus potentially
limiting glucocorticoid effectiveness in suppressing
inflammation in vitro studies and in patients with
COPD.78 Overexpression of HDAC2 restores glucocor-
ticoid sensitivity in bronchoalveolar lavage (BAL) mac-
rophages from COPD patients. Theophylline at
concentrations that do not inhibit phosphodiesterase 4
activity enhances HDAC2 activity and functionally
this enhances glucocorticoid effects.78 This effect may
be via phosphoinositide-3-kinase (PI3K)d-induced hy-
perphosphorylation of HDAC2 particularly because
Translational Research
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tients with COPD.78 In a small clinical study of 30 pa-
tients with stable COPD treatment with low-dose
slow-release theophylline plus low-dose inhaled flutica-
sone significantly reduced sputum neutrophils and
improved lung function, and this was associated with
an increase in HDAC2 activity in circulating peripheral
blood monocytes.83 The results of an ongoing phase II
controlled study (https://clinicaltrials.gov/ct2/show/
NCT02130635) on the efficacy of a highly selective
inhaled PI3Kd inhibitor (GSK2269557) in patients
with stable COPD are awaited with interest.
ANTICYTOKINE AND CHEMOKINE TREATMENT IN
COPD
There is ample evidence of enhanced inflammation in
COPD particularly of cytokines linked to cell recruit-
ment and activation.19,84,85 Although many of these
have been proposed to play a role in COPD
pathophysiology, increased levels do not constitute
evidence for a physiological role in disease, which
requires efficacy in clinical trials. However, few trials
of blocking antibodies against cytokines and
chemokines or their receptors have proved successful.
For example, although both tumor necrosis factor a
(TNF-a) and CXCL8 are increased in COPD airways
and sputum, the clinical effects of both anti–TNF-a
and anti-CXCL8 were not encouraging.19 Treatment
with infliximab for 6 months in a randomized,
placebo-controlled trial demonstrated no clinical
benefit but was associated with an increased risk of
lung cancer and pneumonia.86 The lack of effect of
anti–TNF-a in COPD is in stark contrast to the benefi-
cial effect seen in other chronic inflammatory diseases
such as rheumatoid arthritis.87
CXCL1,CXCL5, andCXCL8 are neutrophil chemoat-
tractants whose expression is increased inCOPD airways
and who signal through CXCR2. This suggests that
blocking this common receptor could reduce the chemo-
taxis of neutrophils.19 In a 6-month double-blind random-
ized study, patients with moderate-to-severe COPD
(already on standard therapy) were given 10, 30, or
50 mg of the small molecule inhibitor of CXCR2
MK-7123 (also known as SCH527123) or placebo
daily.88 The primary endpoint was change from baseline
in postbronchodilator FEV1 (www.clinicaltrials.gov NC
T01006616). MK-7123 resulted in a dose-dependent
67 mL improvement in FEV1 over placebo, a significant
reduction in sputum neutrophils and reduced levels of
sputum and plasma matrix metallopeptidase-9 and mye-
loperoxidase. The effect seen was greater in smokers
compared with ex-smokers.88
In addition, although IL-1b amplifies inflammation
and its concentration is increased in the sputum of pa-tients with COPD, canakinumab, an anti–IL-1b-specific
antibody, also had no clinical efficacy in COPD after
45 weeks of treatment (ClinicalTrials.gov identifier,
NCT00581945). IL-6 concentrations increased in
sputum, BAL, and serum, and because of its role in
amplifying inflammation may be a useful therapeutic
agent in COPD. An IL-6R–specific antibody (tocilizu-
mab) is effective in patients with rheumatoid arthritis
who are refractory to anti–TNF-a therapy89 but no
studies have been performed in COPD patients.
Human neutrophil elastase is elastolytic, proinflam-
matory, and increases mucus secretion, and there is
increased release from neutrophils in COPD and
enhanced levels in sputum and BAL from patients with
COPD. Despite AZ9668 being effective in animal
models of COPD, no clinical improvement was observed
for more than a period of 3 months in patients with
COPD.90 Other proliferative agents such as epidermal
growth factor whose expression is increased in COPD
and enhances mucus hypersecretion have been proposed
to have pathophysiological roles in COPD. Despite the
effectiveness of gefitinib, for example, in some patients
with lung cancer, an inhaled epidermal growth factor re-
ceptor (EGFR) inhibitor (BIBW-2948) did not substan-
tially reduce gene expression or show any clinical
benefit in patients with COPD.91
There has recently been much interest in the potential
of targeting IL-5 in COPD patients, especially for
treatment during exacerbations. Although IL-5 is associ-
ated with a Th2-driven immune response, there is evi-
dence showing increased IL-5 levels in COPD patients
during exacerbations and also in specific COPD pheno-
types, including asthma-COPD overlap syndrome.92 It
is estimated that 16% of COPD patients have the
asthma-COPD overlap syndrome.93 These patients are
normally younger and suffer from higher frequency
and severity exacerbations compared with other COPD
patients. A decrease in soluble IL-5Ra is associated
with the resolution of viral-driven COPD exacerbation.92
Benralizumab, an anti–IL-5RaMAb, did not reduce the
rate of acute exacerbations of COPD. However, the
results of prespecified subgroup analysis support further
investigation of benralizumab in patients with COPD
and eosinophilia.94 Numerous other drugs targeting spe-
cific inflammatory mediators are under investigation for
COPD, and these include antibodies directed against
IL-18, IL-22, IL-23, IL-33, TSLP, and Granulocyte-
macrophage colony-stimulating factor (GM-CSF). It is
unlikely that mouse models of COPD will be anymore
predictive than those seen to date and it is only going
to be possible to determine whether this approach will
work is to try these approaches in COPD itself.
As seen in asthma, patient selection is likely to be crit-
ical for obtaining optimal clinical responses with
Translational Research
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patients present with a variable mix of distinct pheno-
types such as emphysema, bronchitis, small airways
disease, frequent vs infrequent exacerbators, or those
with a rapid decline in lung function, which are indepen-
dent of genetic background.95 Importantly, the level of
chronic airflow obstruction is not enough to encompass
the diversity of presentation of COPD.96 The inclusion
of inflammatorymarkers in addition tomore defined sub-
phenotyping of COPD patients may enable the detection
of COPD endotypes which, as seen with anti–IL-5Ra
MAb treatment, has the potential for a more personalized
treatment approach in the future as opposed to the present
relatively ineffective global treatment strategy of gluco-
corticoids and LABA.CONCLUSIONS
The concept of phenotyping is not only an important
step toward improved understanding of disease, but is
also required to tailor asthma and COPD management
to the individual patient needs as part of stratified med-
icine. Ultimately, phenotypes will evolve into asthma
‘‘endotypes,’’ which combine clinical characteristics
with identifiable mechanistic pathways.
Clinical relevance of phenotyping in airways disease
has been exemplified by randomized trials in asthma,
for example, in which therapeutic efficacy could be
predicted or improved by taking inflammatory charac-
teristics into account. Neutrophilic airway inflammation
was found to be associated with poor corticosteroid re-
sponses and corticosteroid treatment guided by eosino-
philic inflammation led to better disease outcome than
standard clinical management. In addition, asthma ther-
apy with new biologicals, for example anti–IL-5 or
anti–IL-13, appears to be far more effective if patients
are selected using cellular (eg, eosinophils) or molecu-
lar (eg, periostin) biomarkers. This demonstrates the
key role of individual inflammatorymediators in driving
the inflammatory response in asthma and highlights the
need for accurate disease (sub)phenotyping to optimize
disease management and drug development.
The use of novel inflammatory mediator-targeted
therapeutic agents in selected patients with asthma or
COPD and the detection of markers of responsiveness
or nonresponsiveness will allow a link between clinical
phenotypes and pathophysiological mechanisms to be
delineated reaching the goal of endotyping each pa-
tient. Early blood or exhaled biomarkers of subpheno-
types and/or treatment response will be important to
ensure that patients can be taken off a treatment early
if it is ineffective to reduce the risk of any possible
adverse effects in an adaptive design clinical study
or in real life.ACKNOWLEDGMENTS
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